Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Ultrasensitive ctDNA monitoring reveals early predictors of immunotherapy response in advanced cancer.

A whole-genome tumor-informed assay tracking about 1,800 mutations was used on 227 plasma samples from 39 people with advanced cancer receiving immune checkpoint inhibitors, and 33% of positive detections were below 100 parts per million.

NPJ Precision OncologyPubMed 41580469DOI 10.1038/s41698-026-01287-3